Serum Creatinine Trajectories To End-stage Renal Disease: The Path To ESRD - The Syndrome Of Rapid Onset End-stage Renal Disease - A 100 Consecutive Cohort Analysis In A Mayo Clinic Dialysis Population | 4333
This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Serum creatinine trajectories to end-stage renal disease: The path to ESRD - The syndrome of rapid onset end-stage renal disease - A 100 consecutive cohort analysis in a Mayo Clinic dialysis population
International Conference and Exhibition on Nephrology & Therapeutics
The classic view of CKD-ESRD progression is a predictable, linear, progressive and time-dependent relentless
declining renal function in CKD patients, with predictably increasing serum creatinine values, leading inexorably to ESRD
and need for RRT. The syndrome of rapid onset end-stage renal disease (SORO-ESRD), which we first described in 2010, is
irreversible ESRD rapidly following AKI superimposed on CKD. The contribution of SORO-ESRD to the ESRD population
We retrospectively analyzed the serum creatinine trajectories of 100 ESRD patients on RRT for >/=90 days.
Excluding 9 patients with incomplete data, of 91 ESRD patients, 57M:34F, age range 39-93 years, 31 (34%) including two
RTR satisfied the diagnosis of SOROESRD ? 18M:13F, age 72 (50-92) years. AKI precipitating SORO-ESRD followed pneumonia
(8), ADHF (7), pyelonephritis (4), post-operative (5), general sepsis (3), contrast-induced nephropathy (2), and others (2). Time
between AKI and initiation of RRT was less than one week following cardiac surgery. Incidentally, 7 of 31 (23%) SORO-ESRD
patients were concurrently on RAAS blockade.
SORO-ESRD is not uncommon among the incident US ESRD population. The implications of this phenomenon
are huge with regards to ESRD care planning, AV Fistula first programs and overall CKD care in general and demand further
study. If shown to be this prevalent in multi-center studies, major paradigm shifts must be warranted in the way we practice
nephrology. We have organized a Worldwide SORO-ESRD Consortium of Nephrologists to study this phenomenon in the
Americas, Asia, Africa and Europe
Dr. Onuigbo received his MD at age 23 from the University of Nigeria. US Board-Certified Internal Medicine and Nephrology. Nephrologist/Transplant
Physician/Hypertension Specialist, Mayo Clinic Health System, Eau Claire, WI, USA. Associate Professor, Mayo Clinic, Rochester, MN, USA. Fellow
of the American Society of Nephrology. Regional Director, North-Eastern Region, Mayo Health System Practice-Based Research Network 2009-
2011. Recipient 2010-2011 Mayo MacMillan Scholarship Award. Over 80 publications including editing a major Hemodialysis textbook in 2012.
Described the new syndrome of late-onset renal failure from angiotensin blockade (LORFFAB-2005) and the new syndrome of rapid-onset end-stage
renal disease (SORO-ESRD-2010). Completed an MBA (Healthcare) in May 2012.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals